An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma
Ross Firestone, Alexander M. Lesokhin, Saad Z. Usmani
Abstract
SUMMARY: In the past year, three new bispecific antibodies have received accelerated FDA approval for the treatment of relapsed/refractory multiple myeloma. In this article, we review the available data for these three agents, teclistamab, elranatamab, and talquetamab, and discuss practical considerations for their use in clinical settings while the medical community awaits randomized phase III clinical trial datasets comparing them to standard-of-care regimens.
Topics & Concepts
MedicineBispecific antibodyClinical trialRefractory (planetary science)Multiple myelomaEmbarrassmentOncologyInternal medicineAntibodyImmunologyMonoclonal antibodyPsychologySocial psychologyPhysicsAstrobiologyMonoclonal and Polyclonal Antibodies ResearchMultiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research